Miami, August 10, 2026
Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of preclinical data showing that Telomir-Zn suppressed tumor growth in prostate cancer and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The findings were published in the Journal of Oncology Research and Therapy in a manuscript examining how Telomir-Zn modulates intracellular metals to inhibit JmjC histone demethylases (KDMs) and suppress tumor growth. The company said the research provides scientific support for advancing Telomir-Zn toward its planned Phase 1/2 clinical trial in TNBC. The compound is designed to target metabolic and epigenetic mechanisms that contribute to aggressive cancers, potentially offering a different therapeutic approach from conventional treatments that act directly on downstream epigenetic enzymes.
Telomir-Zn Targets Iron-Dependent KDM Activity
The study identified histone demethylases, particularly the KDM2, KDM5 and KDM6 families, as important targets of Telomir-Zn. These enzymes require intracellular iron to function and can contribute to cancer development by influencing the expression of tumor-suppressor and oncogenic genes. Researchers reported that Telomir-Zn reduced available intracellular iron, thereby inhibiting KDM activity and producing anti-cancer effects in experimental models. A key finding came from iron-rescue experiments, in which restoring iron to treated TNBC cells significantly reversed the compound’s cancer-killing effect. According to the company, this result supports an iron-dependent mechanism rather than nonspecific toxicity. The study also reported a potentially meaningful selectivity window, with Telomir-Zn killing iron-dependent TNBC cells at low concentrations while normal cells remained unaffected at concentrations more than 50-fold higher.
Preclinical Studies Show Tumor and Metastatic Effects
In prostate cancer models, oral Telomir-Zn was reported to suppress tumor growth while reactivating several silenced tumor-suppressor genes, including STAT1, GSTP1, RASSF1A, CDKN2A and MASPIN. The compound also demonstrated anti-tumor activity in multiple TNBC human xenograft models. In HCC1806 xenografts, Telomir-Zn reduced primary tumor size and significantly decreased metastatic dissemination, an important finding given the aggressive nature of TNBC. In another model using BT-549 tumors, combining Telomir-Zn with paclitaxel produced greater tumor reduction than either treatment alone, suggesting potential for future combination approaches. However, the MDA-MB-231 xenograft model did not respond, highlighting the possibility that tumor sensitivity may vary according to specific iron-metabolism characteristics. The company said these differences could eventually support biomarker-based patient selection.
Advertisement
Telomir Pharmaceuticals Prepares for Phase 1/2 Trial
The publication provides a scientific rationale for Telomir Pharmaceuticals’ planned clinical development of Telomir-Zn in advanced or metastatic TNBC. The company believes the therapy could address an important gap by targeting the metabolic dependency that supports excessive KDM activity rather than broadly inhibiting downstream epigenetic machinery. By modulating intracellular iron, Telomir-Zn is designed to interfere with KDM-driven epigenetic silencing and potentially restore tumor-suppressor activity. Telomir Pharmaceuticals said its lead program has received FDA IND clearance for a Phase 1/2 clinical trial in TNBC and intends to evaluate whether the preclinical findings translate into clinical benefit. While the reported tumor suppression, metastatic effects and combination activity are encouraging, the evidence remains preclinical, and the safety and efficacy of Telomir-Zn in humans have yet to be established. The upcoming clinical program will therefore be important in determining whether the proposed iron-modulation strategy can become a viable treatment approach for patients with difficult-to-treat TNBC.
Source: Telomir Pharmaceuticals press release
